Intellect Neurosciences, Inc. (ILNS.OB) Obtains EU Patent for ANTISENILIN® Monoclonal Antibody
Intellect Neurosciences, Inc. (ILNS.OB), a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic agents designed to slow, arrest and ultimately prevent Alzheimer’s disease and other serious disorders, recently announced it has obtained a European patent for ANTISENILIN®, a monoclonal antibody platform for the treatment of Alzheimer’s disease. Intellect Neurosciences’ ANTISENILIN® monoclonal antibody technology is currently being used by major pharmaceutical companies with products already in advanced clinical development. The claims of the issued patent cover the ANTISENILIN® “free-end specific” antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of…